FIGURE 1.

M2‐like macrophage infiltration is associated with poor clinical outcomes. (A) Macrophage enrichment in 19 different solid tumors. The ssGSEA results are shown in a circle plot, with the size of the circles denoting the percentage of patients with NES >0 and q value (FDR) <0.1. (B) The average fraction of immunological subpopulations in lung adenocarcinoma (LUAD) specimens (n = 574). (C and D) Representative images and statistical results of CD206 immunohistochemical staining in LUAD specimens. The tumor specimens collected from patients were divided into a metastatic group (n = 59) and nonmetastatic group (n = 67) according to pathological information and follow‐up information. The inclusion criteria for the metastasis group were those with pathological findings of metastases, including distant and lymph node metastases, or patients with metastases after surgery. The red arrow refers to tumor cells with high expression of CD206. Left scale bar, 400 μm; right scale bar, 100 μm. (E) The relationship between CD206 expression and metastasis‐free survival in LUAD patients. There were 59 cases of low CD206 expression and 56 cases of high CD206 expression. Data are shown as the mean ± SEM. BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CRC, colorectal cancer; GBM, glioblastoma multiforme; HNSC, head‐and‐neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUSC, lung squamous cell carcinoma; meta, metastatic NSCLC; Nonmeta, nonmetastatic NSCLC; NSCLC, non‐small‐cell lung cancer; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma. ***p < 0.001